NEW YORK (TheStreet) -- In Friday's CNBC segment of "Stop Trading," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called InterMune (ITMN) a buy. He sure looks right. Currently, the stock is higher by more than 13%.
"The New England Journal of Medicine came out with a very positive piece on Sunday," about InterMune, Cramer said.
He called the company's pulmonary fibrosis treatment a "drug I truly believe in," and suggested that "InterMune goes higher."
With a short interest north of 37%, a "short squeeze to end all short squeezes" may be in the cards if the stock can push above $111.
>>Read More: Google Is Close to a Deal for Twitch
>>Read More: Best of Kass: Deadhead Tips; 10-Year Yields
-- Written by Bret Kenwell in Petoskey, Mich.
At the time of publication, the author held no positions in any of the stocks mentioned.
This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.